{"id":471331,"date":"2021-04-06T06:03:19","date_gmt":"2021-04-06T10:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471331"},"modified":"2021-04-06T06:03:19","modified_gmt":"2021-04-06T10:03:19","slug":"biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/","title":{"rendered":"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients<\/b><\/p>\n<p class=\"bwalignc\"><i>Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies<\/i><\/p>\n<p>BOULDER, Colo.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.biodesix.com%2F&amp;esheet=52406251&amp;newsitemid=20210406005062&amp;lan=en-US&amp;anchor=Biodesix%2C+Inc.&amp;index=1&amp;md5=5a98cb330c55518cff67e764b3bbff42\">Biodesix, Inc.<\/a> (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability to develop blood-based immunotherapy and pipeline testing strategies. These developments further improve Biodesix\u2019s ability to offer rapid, accurate assessment of patients, which guide physician treatment strategies for their cancer patients.\n<\/p>\n<p>\nU.S. Patent 10,950,348, titled, \u201cPredictive Test for Patient Benefit from Antibody Drug Blocking Ligand Activation of the T-Cell Programmed Cell Death 1 (PD-1) Checkpoint Protein and Classifier Development Methods,\u201d covers a test that classifies patients based on their responses, or failures to respond, to immunotherapies. This diagnostic methodology is designed to stratify patients with lung cancer based on their likelihood to respond to immunotherapies.\n<\/p>\n<p>\n\u201cImmunotherapy drugs have made tremendous headway in the treatment of many types of cancers, including lung cancer and melanoma,\u201d said Robert Georgantas, III, Ph.D., Senior Vice President of Research and Translational Science at Biodesix. \u201cHowever, only a subset of patients benefits from these treatments. Predicting who will or will not respond to immunotherapy is imperative for better stratification of patients by immune response to foster treatment personalization and optimal outcome. Additionally, response prediction can help our biopharma research partners develop drug regimens to improve patient survival with these types of drugs.\u201d\n<\/p>\n<p>\nU.S. Patent 10,870,891, \u201cDiagnostic Test System for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood,\u201d covers a novel method for detecting fragmented ribonucleic acid (RNA) in whole blood samples. The method uniquely purifies and amplifies RNA once it is isolated and can ultimately be used in tests that identify or quantify tumor genes and mutations in a host of downstream applications.\n<\/p>\n<p>\n\u201cThis method is especially valuable because it further improves the performance of our blood-based technologies,\u201d Gary Pestano, Ph.D., Chief Development Officer at Biodesix, said of the novel diagnostic test method. \u201cThe method is incorporated into multiple diagnostic tests, such as the GeneStrat\u00ae test and other pipeline tests. Specifically, the patented methods have applicability across a number of technologies that purify, transcribe and amplify nucleic acids, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), allowing Biodesix to gather important data in a robust and efficient way that can be used to support physicians and patients in making timely treatment decisions.\u201d\n<\/p>\n<p>\n\u201cPatents have historically driven the biotechnology industry forward, but conversely have become harder than ever to obtain. Our recent issuances, across diverse technology fields are good news in light of the increasingly fast pace of the diagnostics sector,\u201d said Scott Hutton, Chief Executive Officer at Biodesix. \u201cThere is significant ongoing research activity at Biodesix, which will lead to future patent filings that will continue to strengthen and broaden our position in the market.\u201d\n<\/p>\n<p><b>About Biodesix<\/b><\/p>\n<p>\nBiodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR\u2122 test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood based Biodesix Lung Reflex\u00ae strategy for lung cancer patients integrates the GeneStrat\u00ae and VeriStrat\u00ae tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood based Nodify Lung\u2122 nodule risk assessment testing strategy, consisting of the Nodify XL2\u00ae and the Nodify CDT\u2122 tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world\u2019s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.biodesix.com%2F&amp;esheet=52406251&amp;newsitemid=20210406005062&amp;lan=en-US&amp;anchor=biodesix.com&amp;index=2&amp;md5=a97ebb08b498028d9f528e2ab34a3e4d\">biodesix.com<\/a>.\n<\/p>\n<p><b>Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201copportunity,\u201d \u201cgoals,\u201d or \u201cshould,\u201d and similar expressions are intended to identify forward-looking statements. Such statements are based on management\u2019s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it\u2019s possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix\u2019s most recent annual report on Form 10K, filed March 16, 2021. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210406005062\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210406005062\/en\/<\/a><\/span><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Jordona Jackson Smith<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Jordona@jacksonbio.com\">Jordona@jacksonbio.com<br \/>\n<\/a><br \/>(805) 674-7347\n<\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Chris Brinzey<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:chris.brinzey@westwicke.com\">chris.brinzey@westwicke.com<br \/>\n<\/a><br \/>(339) 970-2843\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Colorado<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Other Health General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210406005062\/en\/869226\/3\/Biodesix_r_rgb.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies BOULDER, Colo.&#8211;(BUSINESS WIRE)&#8211;Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability to develop blood-based immunotherapy and pipeline testing strategies. These developments further improve Biodesix\u2019s ability to offer rapid, accurate assessment of patients, which guide physician treatment strategies for their cancer patients. U.S. Patent 10,950,348, titled, \u201cPredictive Test for Patient Benefit from Antibody Drug Blocking Ligand Activation of the T-Cell Programmed Cell Death &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471331","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies BOULDER, Colo.&#8211;(BUSINESS WIRE)&#8211;Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability to develop blood-based immunotherapy and pipeline testing strategies. These developments further improve Biodesix\u2019s ability to offer rapid, accurate assessment of patients, which guide physician treatment strategies for their cancer patients. U.S. Patent 10,950,348, titled, \u201cPredictive Test for Patient Benefit from Antibody Drug Blocking Ligand Activation of the T-Cell Programmed Cell Death &hellip; Continue reading &quot;Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T10:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients\",\"datePublished\":\"2021-04-06T10:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/\"},\"wordCount\":1022,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/\",\"name\":\"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-06T10:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/","og_locale":"en_US","og_type":"article","og_title":"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients - Market Newsdesk","og_description":"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies BOULDER, Colo.&#8211;(BUSINESS WIRE)&#8211;Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability to develop blood-based immunotherapy and pipeline testing strategies. These developments further improve Biodesix\u2019s ability to offer rapid, accurate assessment of patients, which guide physician treatment strategies for their cancer patients. U.S. Patent 10,950,348, titled, \u201cPredictive Test for Patient Benefit from Antibody Drug Blocking Ligand Activation of the T-Cell Programmed Cell Death &hellip; Continue reading \"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T10:03:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients","datePublished":"2021-04-06T10:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/"},"wordCount":1022,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/","name":"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-06T10:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-issuance-of-two-u-s-patents-expands-coverage-of-diagnostic-methods-to-improve-care-for-cancer-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471331"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471331\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}